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ABSTRACT 
 
Methadone maintenance therapy (MMT) has been used for opioid dependence as one of the 
harm-reduction approaches. It is also effectiveindirectlyto prevent the wide spread of HIV-
related risks such as needle sharing behaviour and illicit drug use. With low costs calculated per 
patient, MMT has been put as top priorities on reducing opioid dependencies in Malaysia. 
However, the effective dose strategy of the therapy is still open to debate. The study aimed to 
investigate the potential of methadone trough concentration (Ctrough)tobe a surrogate marker for 
such purpose. We conducted a 9-months prospective study to assess the relationship between 
Ctrough and Dose (D) of methadone. A total of 115 subjects fulfilled the inclusion criteria and had 
given their consents to participate. Two (2) ml of the trough blood samples (Ctrough) were taken 
and centrifuged within 4 hours from the time taken at 5,000 Gfor 5 minutes. The resulting serum 
samples were kept at -20°C until further analysis. The methadone concentration was determined 
by using a validated method for Methadone ELISA kit. The patients were subjected to another 2 
follow ups at 3 months interval each and the same method of serum sampling was applied. Initial 
correlation reveals significant positive correlation between the two variables in every follow up, 
ranging between r=0.403-0.419 (p<0.005). Further regression analysis reveals that the coefficient 
of determination, r
2
 was poor with only 15-17% of variation in the Ctrough can be explained by the 
changes in clinical doses (p<0.005). Based on the results, we conclude that daily clinical dose 
poorly predicts methadone Ctrough for the purpose of dosing adjustment and monitoring of 
therapy.  
 
Keywords: Methadone dose, trough serum methadone concentration, methadone dose and 
serum concentration relationship. 
  
Corresponding Author:Nor Ilyani Mohamed Nazar(norilyaninazar@gmail.com, +60-
0134807703, +609-5716400 ext 4891). 
 
 
 
 
 
 
INTRODUCTION 
 
The use of illicit drugs particularly the intravenous drug use (IDU) has been consistently shown a 
close relationship in communicating Human Immunodeficiency Virus(HIV)anditsfurther 
complicationsofacquired immunodeficiency syndrome (AIDS) in the population [1-4]. In many 
Asian countries including Malaysia, heroin is still regarded as the major used illicit opiates 
compared to other class of abused drugs which explains the 70% of HIV infected patients are 
amongst intravenous drug users [5]. It has also been estimated that 1 in every 5 intravenous (IV) 
drug users is HIV positive which make up approximately 20% of the IDUs [5,6]. The trend will 
nevertheless increase if no step taken to tackle the problem [7]. In view of this menace, 
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methadone maintenance therapy (MMT) was introduced in patients with opioid use disorders as 
one of the harm-reduction approaches [8-10]. Practicing MMT in various countries shows 
promising results [11-15]. The usage was initially introduced by Professor Vincent P. Dole and 
the late Professor Marie E. Nyswander back in 1965 [8]. In their now famous study, MMT was 
shown to prevent and relieve opioid craving while blocking its euphoric effects [9]. It normalizes 
the somatic, neurological as well as endocrinological dysfunctions associated with prolonged 
opioid use [10]. As results, studies have shown that commitment to such therapy reduced 
cravings and withdrawals which lead to the reduction in illicit drugs use and degrading notorious 
spread of HIVin the community [12, 14,16-18].  
 
However determining an optimal dose is a major challenge [19,20] due to its complex 
disposition mediated by polymorphic enzymes, transporters and receptors [21-27]. The 
consequent pharmacokinetic variability makes similar doses not yielding similar plasma 
concentrations or clinical effects in different subjects. Its long half-life and wide inter-patient 
variability in its clearance also make methadone use difficult to optimize.“Higher is better” 
notion generally holds through with methadone maintenance dose to ensure retention in 
programs. It was found that a dose of 50 mg/day was associated with higher retention rates 
compared to lower doses [28]. Similarly, patients maintained on 60mg/day or higher had better 
treatment outcomes and indeed, doses exceeding 100 mg/d have been used safely and effectively 
in long-term maintenance treatments [29]. Similar observations were also reported in other 
studies [30-32]. 
 
Nevertheless, several other studies failed to find a clear association between positive treatment 
outcomes and high doses. In Canada for instance, both higher and lower dosage protocols have 
been clinically implemented with parallel end results in different populations. Older and more 
motivated patients were given the low dose (40 mg) whereas higher doses (100 mg) were given 
to less motivated and more chronic users [33].  In an earlier studywhere a dose of 30 mg daily 
was used, it was reported that patients remained on treatment for 6 to 12 months and scored 
higher in terms of outcomes, such as reduced illicit heroin consumption, reduced arrest due to 
criminality and full-time employment compared to the dropouts [34] even at this low dose. A 
study reported on continuing use of illicit drugs and cravings despite high methadone dosage 
[35].  
 
Blaneyet al (1999) reported lack of significant difference in any of the outcome variables 
attributable to methadone doses [36]. Based on those findings, it has been suggested that the 
dosage of methadone should be individualized instead of relying solely on the population data. 
 
In this study, we assessed dose-Ctrough relationship in order to further propose on monitoring of 
methadone trough serum concentration (Ctrough) instead of dose (D) solely, in patients with 
MMT. We also investigate other environmental factors which may contribute to the variability of 
both methadone clinical dose and its Ctrough. In conducting this study, we assumed that methadone 
Ctrough at steady state reflects the receptor level of methadone concentration in exerting the 
clinical effects.  
 
 
 
International Journal of Pharmaceutical Science and Health Care                              Issue 4, Vol 2.March- April 2014                    
Available online on http://www.rspublication.com/ijphc/index.html                                                 ISSN 2249 – 5738 
R S. Publication, rspublicationhouse@gmail.com. Page 4 
 
 
 
MATERIALS AND METHODS 
 
Study Design 
This is an observational prospective study. Patients were required to undergo twice follow-ups 
with 3 months period interval.  
 
Ethics Approvals 
The study was approved by the UniversitiSains Malaysia (USM) Ethical Committee and was 
registeredwith the National Medical Research Registry (NMRR-09-773-4587), Clinical Research 
Centre (CRC), Ministry of Health Malaysia. As the study was multi-centred, similar approvals 
were also obtained from the ethical committee at the International Islamic University Malaysia 
(IIUM).  
 
Inclusion and exclusion criteria 
The inclusion criteria include those aged more than 18 years old, exhibited high treatment 
compliance rate which should not be more than 20% of non-compliance rate, those have been 
under treatment for more than 6 months and willing to participate. The subjects were briefed on 
the study nature 7 objectives and signed the informed consent form. Those who were unfit and 
suffered from severe unstable psychiatry conditions were excluded from the study.  
 
Clinical setting and protocol 
This study was conducted prospectively for 9 months, starting from 1
st
 of April 2010. . The study 
phase was divided into a baseline phase (BL), follow-up 1 (FU1) and follow up 2 (FU2). After 
signing of informed consents, the patients were interviewed using an adopted Brief Treatment 
Outcome Measure (BTOM) questionnaire [37]. This was used to gather socio-demographic, 
history of drug addiction, drug dependency patterns, other drug usage, other psychiatry related 
illness and other issues related to treatment. On their first visit, two ml blood was obtained just 
before their next dose (Ctrough) to determine methadone concentration. Samples were left to 
coagulate at room temperature for 30-45 minutes (not more than 60 minutes). The tubes were 
taken for centrifugation at 5,000 g x 5 minutes and the supernatant or the serum was transferred 
to other pre-labelled empty tubes. These final samples were kept at -20°C until analysis. Other 
treatment observation during the first visit included respective dose and compliance rates, were 
assessed. Any significant comments from the physician were also recorded. Patients were then 
scheduled to the next two consecutive visits approximately three months apart.  
 
For the next two visits, the same sampling methods and data collection protocols were employed. 
Patients were classified as dropouts if they failed to meet the original inclusion criteria, 
transferred to another methadone clinic by their own preference or assigned by the physician in-
charged, hospitalized for more than a month, defaulted treatment for more than a month, jailed or 
died either due to medical problems or any other causes like motor vehicle accidents. Patients 
were considered as deviating if they were suddenly found non-compliant or they declined to 
participate during the process of data collection. Compliance rates were carefully assessed 
individually, especially for patients on take away doses. 
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Methadone Ctrough determination. 
 
The methadone Ctroughwas determined by using a validated methadone enzyme-linked 
immunosorbent assay (ELISA) kit [38]. All reagents and samples were brought into room 
temperature (18-26°C) for at least 30 minutes before use. This was to standardize the 
temperatures of the liquids involved. The reagents and calibrators will then be vortex-mixed for 
15 seconds to produce a homogeneous mixture. The serum and the standard samples would also 
be re-centrifuged at 5,000 G for 1 minute before each use. Five micro litres of serum and 
standard samples were diluted at 1:100 in 1.5ml micro-centrifuge tubes with dilution buffer. 
These samples were again vortex-mixed for 30 seconds in order to produce a homogeneous 
mixture. 
 
Ninety micro litres of each calibrator would be added into the first strip of plain micro-wells in 
duplicates. The same amount of serum and standard samples would be further added in 
duplicates based on the labelled grid which would have been prepared earlier. Thirty micro litres 
of the enzyme conjugate or methadone HRP would be systematically added into each well. The 
micro-plate would further be sealed to avoid evaporation. It would then be gently shaken on the 
shaker for about 1 minute with a rotary motion to produce an even mixture. 100 µl of the content 
would carefully be transferred into the methadone antibody coated wells according to the same 
grid by using a multiple channel pipette before being placed in incubation in the dark at room 
temperature for 1 hour.  
 
Next would be the washing step where the content of the plate would be emptied and 300 µl of 
diluted wash buffer would be added into the wells. Another rotary shaking would be carried out 
for 10 seconds. The plate would then be inverted and vigorously slapped dry on the absorbent 
paper to remove any remaining liquid inside the wells. The washing steps would be repeated for 
another 2 times. This step is critical in ensuring that residual enzyme conjugates, would not skew 
results. After successful completion, 150 µl of TMB solution was added into each well and again 
incubated in the dark room temperature for another 30 minutes. Finally, 50 µl of stopping 
solution would be added into each well and shaken gently with rotary motion for another 5 
seconds. Absorbance would be measured at the dual wavelengths of 450 nm and 650 nm. The 
reading would be done in no more than 30 minutes of yellow colouring development.  
 
To interpret results, OD values of the NSB would be subtracted from each individual OD of the 
calibrators as well as the samples. To plot the calibration curve, the mean value of the zero 
calibrator (0ng/ml) would be calculated. The net OD value of the calibrators and samples (mean 
values of the duplicates) would then be divided by the mean OD value of the zero calibrator and 
multiplied by 100%. 
 
 
[O.D. calibrator (or sample) – O.D. NSB]  x 100% 
[Mean O.D. zero standards – O.D. NSB] 
 
= % of maximal optical density = B/Bo (%) 
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The calibration curve would be plotted by using values of the percentage of maximal optical 
density which is calculated for the standards on the y-axis, and the methadone concentration 
(ng/ml) on the logarithmic x-axis. The methadone equivalent concentrations would be read from 
the calibration curve (Figure 1). Since the dilution method was applied earlier, the results of 
methadone equivalent concentrations would be multiplied by a factor of 100 to obtain the true 
serum methadone concentration. 
 
 
Figure 1: Sample of calibration curve plotted by using the calibrators 
 
Statistical analysis 
SPSS 18 was used as the statistical tool for data analysis. Mean of doses and Ctrough was tabulated 
for each follow up. Pearson correlation analysis was applied to explore the initial relationship 
between Ctroughand doses. Regression analysis was next employed to analyze the regression 
coefficient of the two measured variables.   
 
RESULTS 
Patients’ characteristics  
 
One hundred and twenty eight patients were screened however only 115 patients were enrolled 
and consented. In Follow Up 1 (FU1), 106 patients (92.0%) willingly complied with our study 
protocols and attended the third-month follow ups whereas another 27 patients defaulted in 
Follow Up 2 (FU2) increasing the drop-out rate to 31.0% from the baseline.We took 
approximately 4-5 weeks to complete the data collection at every phase and 3-6 patients were 
seen daily, for 5-7 days of a week. 
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Table 1: Demographic characteristics 
 
No Characteristics Mean (SD) n (%) 
1 Age (years old) 
18-29 
30-44 
45-59 
37.9 (8.1)  
10 (8.7) 
82 (71.3) 
23(20.0) 
2 Treatment duration (years) 2.2 (0.9)  
3 Gender 
- Male 
- Female 
 
 
 
114 (99.1) 
1(0.9) 
4 Source of income  
- Full time 
- Part time 
- Pensioner 
- No specific income 
- Undetermined 
 
 
 
75 (65.2) 
26 (22.6) 
2 (1.7) 
10 (8.7) 
2 (1.7) 
5 Monthly income (RM/month) 
- 500 and less 
- 501-1000 
- More than 1000 
- Undetermined 
898.5 (572.1)  
15 (13.3) 
57 (50.4) 
20 (17.7) 
21(18.6) 
6 Marriage status 
- Divorcee/separated 
- Never married 
- Married 
  
17 (14.9) 
53 (46.5) 
44 (38.6) 
7 Living with 
- Alone 
- Spouse only 
- Spouse and children 
- Parents 
- Siblings/ relatives / friends 
 
 
 
20 (17.4) 
14 (12.2) 
27 (23.5) 
43 (37.4) 
11 (9.7) 
9 Housing type 
- Rental house/room  
- Own house  
- Parents place 
- Sponsored hostel 
- No specific place / homeless 
  
47 (40.9) 
24 (20.9) 
38 (33.0) 
3 (2.6) 
3 (2.6) 
10 HIVstatus 
HIV positive 
- HIV negative 
  
13 (11.3) 
102 (88.7) 
11 Directly observed therapy (DOT)/ 
Take away patients (TA) 
- DOT 
- TA 
  
 
50 (43.5) 
65 (56.5) 
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Descriptive statistics of doses (D) and trough serum methadone concentrations (Ctrough) are listed 
in Table 2. The minimum and maximum doses were the same across the 3 points of data 
collection, without drastic changes of the mean. These were held even with inclusion of dropouts 
(intention-to-treat). On the other hand, in terms of trough serum methadone concentrations, the 
minimum, maximum and the mean were slightly increased compared to the baseline. The 
average dose used was less than 70 mg/day and the mean of methadone Ctroughmeasured was 
lessthan 400 ng/ml. 
 
Table 2: Descriptive analysis of Clinical doses (D) and trough serum methadone 
concentrations, (Ctrough) in each data collection point 
 
Data collection 
point 
n 
Mean (SD) 
Dose (mg/day) Ctrough (ng/ml) 
BL 115 65.3 (26.2) 288.9 (175.3) 
FU1 106 64.5 (25.4) 344.5 (190.5) 
FU2 79 65.3 (27.5) 339.8 (198.4) 
BL=Baseline, FU1=follow up 1, FU2=follow up 2, SD= standard deviation 
 
Bivariate correlation analysis between clinical doses (D) and trough serum methadone 
concentration (Ctrough). 
 
Referring to Table 3, there was a consistent and significantpositive,moderate correlation 
(r=0.403-0.419, p<0.001) between clinical doses and their respective Ctrough. We also performed 
regression analysis to further explore the relationship. Figures 2-4 show scatter plots of simple 
linear regression analysis for doses of methadone versus its serum concentration.  
 
Table 3: Correlation analysis between clinical doses (D) and respective trough SMC 
(Ctrough) 
 
N Data collection points 
 
Correlation, r 
+
 
115 Baseline 0.403** 
 
106 Follow up 1 
 
0.419** 
79 Follow up 2 0.406** 
**p value for correlation is <0.001 
+
 Spearman’s rho correlation analysis 
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Figure 2: Regression analysis between clinical doses (D) with Ctrough at baseline 
 
Figure 3: Regression analysis between clinical doses (D) with Ctroughat Follow up 1 
 
Figure 4: Regression analysis between clinical doses (D) with Ctrough at Follow up 2 
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Even though there occurred a trend of increasing standard deviation (SD) with doses increased, it 
is evident that only 15.1-17.5% of trough serum methadone concentration was explained by the 
changes in clinical doses (p<0.001) (Table 4). The coefficient of determination, r
2
 would not give 
an accurate description to determine serum concentration at given doses as clinical doses (D) 
only explain a little in terms of changes in serum methadone concentration (Ctrough). 
 
Table 4: Linear regression analysis between clinical doses (D) and trough SMC (Ctrough) 
Data collection 
point 
 
Coefficient of 
determination, r
2
 
Regression coefficient, 
Β (95% CI) 
 
p value 
Baseline 
 
0.151 2.60  
(1.43- 3.78) 
<0.001 
Follow up 1 
 
0.175 3.15 
(1.82- 4.47) 
<0.001 
Follow up 2 
 
0.165  2.93 
(1.37- 4.49) 
<0.001 
 
 
Difference analysis in mean/median of trough SMC (Ctrough) and methadone daily dose (D) 
in different categories of patients’ demographic characteristic. 
 
We further analyzed the patients according to their demographic characteristic (Table 5 and 6) in 
order to identify any confounding factors which may also contribute to the variability in trough 
Ctrough and clinical doses (D). Patients who were positive with HIV AIDS reported use of 
significantly lower doses compared to negatively diagnosed patients (p<0.05). The mean Ctroughin 
both categories however, did not reach the level of significance (p<0.1). Patients who  admitted 
to involvement of other family members as opiate users had a higher mean Ctroughcompared to 
those who denied such an involvement (p<0.05). Similarly, a higher mean 
Ctroughwasobservedamong patients on DOT compared to those on the Take Away (TA) regime 
(p<0.05). Patients who admitted to additional unknown doses of methadone have shown a 
significant lower mean of methadone dose compared to those without the extra doses of 
methadone but as expected, the difference in Ctrough did not reach statistical difference. Other 
demographic characteristics did not seem to influence the mean of Ctrough or doses. We further 
analyzed methadone Ctrough-dose relationship after considering these probable co-factors (Table 
7).  
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Table 5: Difference analysis in mean/median of trough SMC (Ctrough) and methadone daily 
dose (D) in different categories of patients’ demographic characteristic 
(categorical data) 
 
 
Variables 
Data 
Distributiona 
n (%) 
Mean/Median 
Statistics p value n (%) 
Mean/Median 
Statistics 
p 
value 
Ctrough D 
Ctrough(SD/IQR) D  
(SD/IQR) 
Source of income 
- Full time  
- Part time  
- No specific income  
 
 
0.000 
0.200 
0.200 
 
 
0.032 
0.200 
0.200 
 
75 (65.2) 
26 (22.6) 
12 (10.4) 
 
219.12 (194.77) 
289.53 (308.33) 
242.72 (222.03) 
 
2.107  
(2)c 
 
0.349 
 
70 (60.9) 
26 (22.6) 
12 (10.4) 
 
65.00 (25.00) 
72.50 (31.25) 
55.00 (47.50) 
 
1.489 (2)c 
 
0.475 
 
Living with 
HIVAIDS 
- HIV negative  
- HIV positive 
 
 
 
0.001 
0.200 
 
 
 
0.200 
0.200 
 
 
95 (88.8) 
12 (11.2) 
 
 
263.94 (265.88) 
196.03 (74.97) 
 
 
-1.652b 
 
 
0.098 
 
 
102 (88.) 
13 (11.3) 
 
 
65.51 (23.47) 
51.15 (25.34) 
 
 
14.35 
(0.51,28.20)d 
 
 
0.042
* 
Involvement of 
other family 
member 
- Not admit  
- Admit  
 
 
 
0.200 
0.200 
 
 
0.200 
0.200 
 
 
54 (56.8) 
41 (43.2) 
 
 
284.65 (146.27) 
365.53 (178.89) 
 
 
-80.88  
(-147.15, 
-14.60)d 
 
 
0.017* 
 
 
57 (57.6) 
42 (42.4) 
 
 
63.33 (25.83) 
70.36 (25.88) 
 
 
 
-7.02 
(-17.46,3.41)d 
 
 
0.185 
           
Current injecting 
behavior 
- 0-3 month 
- 3-6 month 
- >6 month 
- > 1 year 
 
 
 
0.036 
0.035 
0.001 
0.200 
 
 
0.200 
0.200 
0.010 
0.200 
 
 
22 (20.0) 
17 (15.5) 
52 (47.3) 
19 (17.3) 
 
 
255.89 (170.51) 
236.40 (311.18) 
211.96 (250.90) 
290.05 (188.90) 
 
 
 
2.753 
(3)c 
 
 
0.431 
 
 
 
22 (19.1) 
18 (15.7) 
50 (43.5) 
20 (17.4) 
 
 
55.00 (41.25) 
70.00 (32.50) 
67.50 (28.75) 
55.00 (30.00) 
 
 
2.671 
(3)c 
 
 
0.445 
 
 
Directly observed 
therapy (DOT)/ 
Take away patients 
(TA) 
- DOT  
- TA  
 
 
 
 
 
 
 
0.200 
0.200 
 
 
 
 
 
 
0.200 
0.050 
 
 
 
 
 
 
 
39 (41.5) 
55 (58.5) 
 
 
 
 
 
 
357.14 (150.94) 
282.22 (150.53) 
 
 
 
 
 
 
74.91 
(12.26, 
137.56)d 
 
 
 
 
 
 
0.020* 
 
 
 
 
 
 
42 (42.9) 
56 (57.1) 
 
 
 
 
 
 
69.05 (23.95) 
63.84 (27.40) 
 
 
 
 
 
 
5.30  
(-5.32,15.73)d 
 
 
 
 
 
 
0.329 
Methadone extra 
doses/not 
- Without extra doses 
- With extra doses 
 
 
 
0.001 
0.000 
 
 
0.017 
0.200 
 
 
102 
8 
 
 
239.68 (236.86) 
228.08 (190.12) 
 
 
-0.460b 
 
 
0.645 
 
 
107 
8 
 
 
70.00 (30.00) 
47.50 (33.75) 
 
 
-1.973b 
 
 
0.048
* 
Ctrough = trough serum methadone concentration, D=Methadone daily dose, SD=Standard deviation, IQR=Inter quartile range a- Kolmogorov Sminorv test 
(p>0.05 indicate normally distributed data), b- Z stat for Mann Whitney test, c-χ2 stat (df) for Kruskal- Wallis test d- Mean difference (95%CI) for Independent t-
test, e-F value (df) for One way ANOVA test, *-p value <0.05 shows significant difference. 
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Table 6: Correlation matrix of trough SMC (Ctrough) and methadone daily dose (D) at 
baseline in different patients’ demographic characteristic (continuous data) 
 
Variables 
 
1 2 3 4 5 6 7 8 9 10 11 12 
1 Treatment 
duration 
2  
1.000            
3 Years involved 
 
0.031 1.000           
4 Age 
 
0.085 (0.853) 1.000          
5 Income 
 
0.044 0.095 0.087 1.000         
6 Age of first 
exposure 
7  
0.066 (-0.347) 0.070 0.083 1.000        
8 SDS scores 
 
-
0.019 
(-0.182) (0.259) 0.132 0.160 1.000       
9 HIV risk scores 
 
-
0.131 
-0.056 0.039 -0.082 0.152 0.140 1.000      
10 Cigarrette 
smoking 
11  
-
0.012 
0.022 0.050 0.109 -0.173 0.040 0.026 1.000     
12 SFS scores 
 
-
0.097 
0.160 0.062 0.180 (-0.262) 0.132 (-0.201) -0.030 1.000    
13 PFS scores 
 
-
0.063 
0.110 0.021 0.149 (-0.245) (0.203) (-0.212) -0.145 (0.385) 1.000  
14 C trough 
 
0.016 -0.040 -0.093 -0.055 -0.144 -0.001 -0.081 0.110 0.078 0.041 1.000  
15 Dose 
 
-
0.036 
0.048 0.025 -0.015 -0.128 -0.072 0.146 0.013 -0.029 0.014 (0.403) 1.00 
HIV- Human Immunideficiency virus, SFS –Social functioning Scores, PFS – Psychological 
functioning scores, ( )- significant correlation with p value<0.05. All of the binary correlations 
were analyzed by using Spearman’s rho correlation as all showed abnormally distributed data. 
 
Table 7: Dose-serum relationship after considering possible co-variates. 
 
Selected 
cases 
 
n Spearman’s 
rho 
correlation, r 
Coefficient of 
determination, r
2
 
Regression 
coefficient, 
β (95% CI) 
 
p value 
HIV negative, 
without other 
family 
involvement, 
take away 
patients and 
without extra 
doses 
37 0.441* 0.195 2.64 
(0.74 – 4.54) 
<0.001** 
*Correlation is significant at the level of 0.05 (2-tailed) 
**Regression analysis is significant at the level of 0.001 (2-tailed) 
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Figure 5: Serum-dose relationship after considering significant patients’ characteristics 
 
It was clearly shown (Figure 5) that approximately only 20% of the changes in serum methadone 
concentration can be explained by the changes in doses which are very much in support of prior 
analysis. 
 
 
DISCUSSIONS 
 
Methadone Maintenance Therapy 
 
Several characteristics have especially made methadone suitable for maintenance therapy [39]. 
Methadone exhibits an excellent oral bioavailability that ranges between 80-90%. The drug also 
exhibits a long half-life allowing for a once daily dosing that can fit well into the patients’ daily 
life. Patients will be able to lead a normal lifestyle and maintain productivity, without the 
deliberating craving. Another important criterion of methadone is its slow onset of action, which 
prevents the fluctuations of drug concentrations in the blood and brain, preventing withdrawal 
symptoms. This allows for a steady state “perfusion” of the drug at its site of action on the 
specific opioid receptors and other sites involved [40]. MMT is a life-long commitment. The 
longer the patients receive MMT the better the outcome and this has been used by detractors who 
saw MMT simply as replacing one dependency with another [41]. A longitudinal prospective 
cohort study showed a long term continuous improvement in the quality of life of patients on 
long durations that ranged from 3 to 12 months and this has also supported long term use of the 
treatment [42]. The benefits are maintained in patients with psychiatric co-morbidity who also 
showed improvements including longer treatment retention, reduction of illicit drug use and 
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reduction in HIV-related risks behaviour [43]. Similarly, providing methadone in incarcerated 
settings are also effective but the therapy has to be continued post-release [44]. It was introduced 
especially to prevent the wide spread of HIV- related risks such as needle sharing behaviour and 
illicit drug use. With low costs calculated per patient, MMT has been put as top priorities on 
reducing opioid dependencies in Malaysia. 
 
Gossop M et al has undertaken a big study called the National Treatment Outcome Research 
Study (NTORS). The majority of patients in the study demonstrated improvements in each 
domain measuring illicit drug use, criminal behaviour, withdrawal symptoms, HIV AIDS risk 
behaviour, health status and overall socioeconomic position as well as quality of life [45]. A 
similar study conducted in Malaysia produced similar trends of success with improvements in 
the quality of life in patients undergoing MMT. Retention rate was 63.6% after 2 years and 
significant improvements were documented in terms of physical and psychological health, socio-
economic status and existence of supportive environment (p<0.001) [46].  
 
However, the dosing strategy of this therapy, in certain circumstances was open to doubt. With 
the hypothesis of a personalized methadone therapy and methadone Ctrough may possibly be a 
surrogate marker for such purpose, we accordingly, conducted a 9-months prospective study to 
assess the relationship between Ctrough and Dose (D) of methadone. 
 
Relationship between current methadone clinical doses (D) with respective trough serum 
methadone concentration (Ctrough). 
 
Initial analysis yielded a significant fair correlation between clinical doses and methadone Ctrough 
(r=0.4, p<0.001). However, on further regression analysis, only a poor relationship was observed 
between the two with only about 20% (r
2
) of the changes in methadone serum concentration 
explained by changes in dose (p<0.05). This finding is not surprising given that methadone 
undergoes polymorphic metabolism mediated by several polymorphic enzymes like CYP3A4 
and CYP2B6, apart from being influenced by the also polymorphic P-gp. Environmental factor 
could also play a role in this poor relationship. In our study, patients with HIV AIDS seemed to 
require lower methadone doses compared to HIV negative patients (p<0.05) to produce an 
essentially similar Ctrough although this group of HIV positive patients received no anti retroviral 
therapy. A study suggested the development of methadone antibodies in HIV positive patients 
that increased serum methadone [47]. Further studies are however needed to validate the 
findings. DOT patients also yielded a higher concentration compared to those on take away 
regimes (p<0.05) probably because of a more ascertained administration of the methadone dose. 
A further difficulty occurred taking into consideration that eight patients admitted to extra doses 
of methadone. These patients had a significantly low methadone dose prescribed (p<0.05) for a 
comparable Ctrough. Mean doses at all the three follow up visits, were less than 70mg/day yielding 
a mean concentration of less than 400ng/ml. As alluded, this could be increased to clinical 
response especially taken into account our previous and other studies that suggested a minimum 
dose of 80mg/day and keeping serum racemic methadone concentration between 400-700ng/ml 
[48,49].  
 
The monitoring serum concentrations of methadone has been previously suggested by Wolf et al. 
in (1992) who reported a high correlation between doses and plasma concentrations (r=0.89) 
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[50]. Subsequent studies however produced contradictory results. One study found a fair 
correlation (r=0.36) that improved with the exclusion of those with co-administered drugs 
(r=0.53). A poor correlation was however found by another group who studied patients with co-
dependencies (r=0.25) [51]. Indeed, the correlation between methadone doses and methadone 
plasma/serum concentrations was variable (r=0.20-0.55, p<0.05) [49]. Another study that 
attempted to divide between patients with higher and lower doses found that patients on lower 
doses of methadone (<80mg) yielded a better correlation between dose and concentration 
(r=0.799, p<0.001) compared to patients on higher doses (r=0.004, p=0.980) [52]. The reports 
however failed to report regression analysis which would be useful to describe a bivariate 
relationship. 
 
Pharmacogenomics of methadone 
 
Genetic contribution [21, 49] are increasingly seen as important factor that can impact on the 
pharmacology of drugs including methadone. Most processes in pharmacology are not passive 
but mediated by some very specific proteins that in turn are products of gene expression. To 
exert its effect, drugs like methadone need to transverse membranes to reach their sites of action. 
Although most of these transfers are not simply passive diffusion across membranes/cells, 
generally, a lipid-soluble drug is favored. Methadone is a poorly water-soluble drug. Methadone, 
like any other exogenous substances, needs to be eliminated as it is not endogenous. For drug 
elimination, the kidneys play a pivotal role, excreting water-soluble substances which methadone 
is not. Prior to this renal elimination process, methadone undergoes metabolism mediated by 
several genetically polymorphic enzymes that include CY2B6 and CYP3A4. Prior to or 
subsequently, methadone is transported across cells and membranes with the help of some 
transporter proteins like Pgp. Methadone does not have a direct pharmacologic effect. To exert 
its effect, methadone needs to bind to some specific receptors that include the various forms of 
opiate receptors. All these mediators for transfers across cells and membranes, metabolism and 
effects are dependent on genes for their formation and functions and these genes are frequently 
polymorphic.  
 
Methadone, is a drug with a large inter-individual variability and has a narrow therapeutic index. 
These are caused by the genetic polymorphisms in genes coding for transporter proteins (p-
glycoprotein), methadone metabolizing enzymes and µ opioid receptors [21]. P-gp is a member 
of the subfamily B of the ATP-binding cassette (ABC) superfamily. It is a trans-membrane 
protein of 1280 amino acids that is composed of two homologous sequences, each containing six 
trans-membrane domains and an ATP binding domain . P-gp is encoded by the ABCB1 (MDR1) 
gene. Being a substrate, its effects are therefore influence by the genetic polymorphism of P-gp 
that may inhibit transmembrane transfers of the drug manifested by reduced plasma 
concentrations and effects.  It has been postulated that gene ABCB1 polymorphisms may 
influence the plasma methadone concentration and dosing requirements [22], however, the 
findings were inconclusive [23]. As methadone is a lipid soluble drug, it therefore requires 
biotransformation before it gets eliminated. Several enzymes have been associated with its 
metabolism and they include CYP 3A4, CYP3A5, CYP2C9, CYP2C19, CYP 2D6, CYP 2B6 
and CYP1A2. These enzymes are genetically polymorphic and their polymorphisms impact on 
methadone metabolism.    
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CYP3A4 isozyme, also found in the gastrointestinal tract, metabolizes methadone before it 
reaches systemic circulation causing a first pass effect on methadone. Genetic variations in 
CYP3A4gene influence the severity of side effects and methadone withdrawal. [24, 25]. Apart 
from CYP3A4, CYP2B6 isozyme that is found in the liver, with is also important in methadone 
metabolism. Although thought to be unimportant in drug metabolism, there is a growing interest 
towards CYP2B6 polymorphisms and its clinical significance. Its substrate list has expanded 
recently and there are now evidence for its cross-regulation with CYP3A4, UGT1A1 and several 
hepatic drug transporters by the nuclear receptors pregnane X receptor and constitutive 
androstane receptor [26]. 
 
Methadone acts on the µ opioid receptor (MOR) especially OPRM1[53]. MOR is also the main 
molecular target of the active biotransformation products of heroin (6-monoacetylmorphine and 
morphine), as well as most opiate and opioid analgesic medications such as oxycodone, 
hydromorphone, and fentanyl, each of which has major potentials for addiction [27]. Abuse of, 
and addiction to these MOR-directed agents constitutes a major addiction problem [54].  
 
CONCLUSION AND RECOMMENDATION 
 
Clinical dose was found to be poorly predicts trough serum methadone concentration which 
suggests that Ctrough may not possibly be a surrogate marker to predict the clinical outcome of 
methadone. However, further studies are needed to substantiate the relationship between 
methadone Ctrough and patients’ genotypes in which we hope will chart future paths towards 
personalized medicine for methadone. 
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